Overactivation of both Polo-like kinase-1 (Plk1) and Aurora-A is linked to cancer development, and small-molecule inhibitors that target these kinases are currently tested as anticancer drugs. Here, we discuss recent advances in the understanding of the functional crosstalk between Plk1 and Aurora-A before and during mitosis. Several recent findings have led to a better appreciation of how the activities of these distinct mitotic kinases are intertwined. Such insight is important for the expected utility of small-molecule inhibitors targeting Plk1 or Aurora-A, and it might help us to improve their application. [Cancer Res 2009;69(11):4555-8] 
Introduction
Progression through the cell cycle is, to a large extent, controlled by protein phosphorylation. Besides the cyclin-dependent kinases (Cdks), the Aurora and Polo-like kinases (Plks) have emerged as major regulators of cell-cycle-dependent protein phosphorylation (1, 2) . Of the diverse Plks, the role of Polo-like kinase-1 (Plk1 in humans and its Saccharomyces cerevisiae Cdc5, Schizosaccharomyces pombe Plo1, Drosophila Polo, and Xenopus Plx1 homologs) is best understood. Plk1 has been implicated in the regulation of centrosome maturation, bipolar spindle assembly, sister chromatid cohesion, activation of APC/C, and initiation of cytokinesis (1) . In addition to mitotic functions, Plk1 participates in the regulation of the G2/M transition. Although activity of Plk1 is redundant for unperturbed mitotic entry, Plk1 becomes essential for the cell cycle restart after repair of damaged DNA (checkpoint recovery) or despite persisting DNA damage (checkpoint adaptation) (3) . A large array of Plk1 substrates has been identified that could explain its diverse functions in cell division (1) . However, until recently, it was unclear how Plk1 itself is regulated in a cell-cycle-dependent manner.
Plk1 consists of a conserved kinase domain and a C-terminal phosphopeptide-binding module known as a polo-box domain (PBD) (ref. 4) . In the absence of a bound ligand, the PBD forms an intramolecular interaction with the kinase domain, which inhibits the basal kinase activity. Based on these studies, a model was proposed in which phosphorylation-dependent binding of the PBD to substrates primed by another kinase ( for instance, Cdks and/or Plks) releases the kinase domain and simultaneously targets Plk to specific subcellular structures (4) . Nonetheless, studies aimed at understanding Plk1 activation have thus far been limited to indirect measurements of the kinase activity in vitro or to the use of phosphospecific antibodies directed to substrates of Plk1. The recent development of a specific FRET-based biosensor for Plk1 in combination with quantitative immunofluorescence approaches has made it possible to measure Plk1 kinase activity in individual cells and has thus allowed for a better temporal resolution of Plk1 activation in vivo (5, 6) . Also, FRET-based biosensors have the additional advantage of being able to monitor the balance between kinase activity and activities of the opposing phosphatases in vivo, which arguably is more relevant for cellular events than the activity of a kinase alone. These advances in studying cell-cycle-dependent protein phosphorylation in single cells has led to the somewhat surprising finding that Plk1 is initially activated early in G2, many hours before mitotic entry (6).
Aurora-A and hBora Activate Plk1 at the G2/M Transition
Expression of Plk1 is cell cycle regulated; basal levels are present during interphase, expression is increased in late G2, and degradation occurs during mitotic exit (1) . The expression level of Plk1 correlates with a rise in kinase activity at the G2/M transition, reaching maximum activity during mitosis. Phosphopeptide mapping and mass spectrometric analysis identified pThr-210 (Thr-201 in Plx1) in the T-loop of the kinase domain as a major posttranslational modification of Plk1 during mitosis (7, 8) . Moreover, mutational analysis in which Thr-210 was replaced by aspartic acid has demonstrated that the addition of a negative charge in the T-loop leads to constitutive activation of Plk1 (9) . Several kinases (including Protein kinase A; Ste20-like kinase (Slk); and its Xenopus homolog, xPlkk1) have been shown to phosphorylate the Thr-210 residue of Plk1 in vitro (8, 10, 11) . However, the identity of the kinase activating Plk1 in vivo has long remained elusive.
Recently, we and others have demonstrated that Aurora-A is responsible for the initial phosphorylation of Plk1 at the G2/M transition (refs. 6, 12) (Fig. 1A) . On centrosomes, pThr-210-Plk1 first appears during G2 before centrosome separation and gradually increases, reaching the highest levels during mitosis. Depletion of Aurora-A by RNAi as well as inhibition of Aurora-A activity by a small-molecule inhibitor, MLN-8054, interfered with the appearance of pThr-210-Plk1 at centrosomes in prophase, indicating that Aurora-A is required for pThr-210 modification of Plk1 in vivo (6) . Moreover, quantitative immunofluorescence analysis confirmed a tight correlation between pThr-210-Plk1 appearance at the centrosomes and the rising activity of Aurora-A kinase. 1 In addition, in prophase, pThr-210-Plk1 is also present at kinetochores (6, 13) , but the exact timing of Thr-210 phosphorylation at kinetochores still needs to be resolved. Interestingly, the kinetochore staining of pThr-210-Plk1 was also affected by the inhibition of Aurora-A (6). At present, it is unclear whether the kinetochore pThr-210-Plk1 signal represents the Plk1 that was initially phosphorylated by Aurora-A at centrosomes and subsequently underwent nuclear translocation, or whether Aurora-A, or another Aurora-A-dependent kinase may directly modify Plk1 at kinetochores. Similar to Plk1, Aurora-A kinase levels rise during G2 and peak in early mitosis (14, 15) . Activation of Aurora-A requires various cofactors, including TPX2, Ajuba, PAK1, Hef1, and hBora, whereas premature activation of Aurora-A is prevented by Protein phosphatase-1 (PP1)-dependent dephosphorylation of an autocatalytic residue (14) . The best understood coactivator of Aurora-A is TPX2, which helps Aurora-A adopt the active conformation, inhibits its inactivation by PP1, and targets Aurora-A to the mitotic spindle (14) . However, TPX2 is not likely to regulate the initial activation of Aurora-A on centrosomes, as it resides in the nucleus before nuclear envelope breakdown. Interestingly, hBora expression peaks during G2 and drops rapidly during mitosis, which makes it a suitable candidate for the activation of Aurora-A prior to mitosis (16, 17) . hBora forms a protein complex with Plk1 during G2 (6, 12, 16) . Interestingly, efficient interaction of hBora with Plk1 has been reported to require priming phosphorylation of hBora by Cdk1 and a functional PBD domain of Plk1 (16); however, another report indicates that, to some extent, Bora can bind to Plk1 in a phosphorylation-independent fashion (12) . Importantly, hBora dramatically enhances the ability of Aurora-A to directly phosphorylate Thr-210 of Plk1 in vitro (6, 12) . This effect seems to be specific toward Plk1, as phosphorylation of other substrates like Histone H1 and Aurora-A itself does not significantly change in the presence of hBora (6, 12) . In good agreement with the essential role of pThr-210 modification in the activation of Plk1, depletion of Aurora-A or hBora delays mitotic entry and blocks checkpoint recovery (6, 12) . Interestingly, depletion of hBora by RNAi does not lead to the formation of a monopolar spindle (16), a typical mitotic phenotype of inhibition of both Plk1 and Aurora-A. Thus, it appears that cells that enter mitosis do not depend on hBora anymore and manage to activate Plk1 via an hBora-independent mechanism. Similarly, hBora depletion does not seem to block the activity of Aurora-A toward substrates other than Plk1.
Using a FRET-based probe that monitors the phosphorylation status of a modified Plk1 substrate, we were able to follow phosphorylation of a Plk1 target throughout the cell cycle in live cells (6) . The signal of the Plk1 FRET probe depended on Plk1 Thr-210 integrity and was greatly enhanced in cells expressing a Thr-210 phospho-mimicking mutant, indicating that Thr-210 Figure 1 . Mechanisms regulating activation of Plk1. A, during G2, Aurora-A, in complex with its cofactor hBora, phosphorylates Plk1 at Thr-210. Activated Plk1 phosphorylates Cdc25C and Wee1, which induces activation of cyclin B-Cdk1 complexes and promotes mitotic entry. Although Plk1 is activated in G2 both during unperturbed growth and after recovery from a DNA-damage checkpoint, it is only essential for mitotic entry during checkpoint recovery. Aurora-A can also directly activate Cdc25B by phosphorylation at Ser-353 (32, 33) . B, during mitosis, active Cdk1 primes hBora for interaction with and phosphorylation by Plk1, which, in turn, leads to proteasomal degradation of hBora. Aurora-A is now free to interact with TPX2, a complex that is necessary for bipolar spindle assembly. Phosphorylation of pThr-210-Plk1 during mitosis is maintained by thus far unidentified kinases (dashed lanes). Conversely, pThr-210-Plk is removed by PP1 in complex with its regulatory subunit MYPT1.
phosphoryltion plays a crucial role in the regulation of Plk1 activity in human cells. At the G2/M transition, Plk1 is enriched at centrosomes and kinetochores and could therefore potentially phosphorylate targets both in the cytoplasm and in the nucleus. Using the FRET-based probe, we noticed that Plk1-dependent phosphorylation could first be observed in the nucleus f5 h before mitosis, after which the phosphorylation gradually increased both in the nucleus and cytoplasm until reaching its peak levels during mitosis. Importantly, this shows that Plk1 activity is present in the nucleus 5 h before mitosis, but does not exclude the possibility that Plk1 activity could be present on the centrosomes or the kinetochores at even earlier time points. Indeed, Plk1 phosphorylated on Thr-210 can be observed on centrosomes well before centrosome separation during G2.
Plk1 Targets Bora for Degradation during Mitosis
During mitosis, hBora is phosphorylated by both Cdk1 and Plk1 (refs. 16, 17) (Fig. 1B) . Phosphorylation of hBora by Plk1 creates a phosphodegron recognized by the hTrCP subunit of the SCF ubiquitin ligase that targets hBora to proteasomal degradation (16, 17) . As hBora competes with TPX2 for a binding site on Aurora-A (16), degradation of hBora during mitosis may initiate a switch toward the formation of TPX2-Aurora-A complexes and thus redirect its kinase activity toward distinct substrates. It is well established that Plk1 is required for Aurora-A targeting to the centrosomes and spindle poles, which may indeed be executed by controlling the levels of cytoplasmic hBora (16, 18) .
Because of the degradation of the essential cofactor hBora during mitosis, it is not likely that the same mechanism that is responsible for the initial activation of Plk1 during G2 would also apply during mitosis. Similarly, TPX2 is not likely to promote phosphorylation of Plk1 during mitosis, as depletion of TPX2 did not affect pThr-210-Plk1 (6). Either Aurora-A employs yet another cofactor to phosphorylate Plk1, or, alternatively, another kinase takes over to activate Plk1 later in mitosis. An attractive candidate for this function has been identified in Xenopus, in which xPlkk1 kinase appears to be both a substrate and a modifier of Plx1 (19) . Indeed, the human Slk homolog can phosphorylate Plk1 in vitro, but, thus far, convincing evidence for its role in activation of Plk1 in vivo is missing (10) . Interestingly, the Thr-210 site in Plk1 is not only regulated by an upstream kinase, but phosphorylation is also actively removed by PP1C during mitosis (13) . Priming phosphorylation of the PP1C regulatory subunit MYPT1 is required for the interaction with Plk1 and for its subsequent dephosphorylation (13) . Identification of an inhibitory phosphatase for Plk1 indicates that the phosphorylation at Thr-210 and hence Plk1 activity is fine tuned in a spatiotemporal manner throughout mitosis.
Plk1 and Aurora-A in Cancer
Importantly, genes encoding human Plk1 and Aurora-A reside in chromosomal regions (16p12.1 and 20q13, respectively) frequently amplified in various tumors (15, 20) . In some tumors, elevated levels of Plk1 correlate with poor prognosis (20) . Small-molecule inhibitors of Plk (BI-2536) and Aurora-A (MLN-8054) kinases have recently been demonstrated to effectively block growth in cultured tumor cells (21) (22) (23) and, with great expectations, are currently being tested for cancer therapy. However, because both Aurora-A and Plk1 are required for multiple steps during cell division, it is possible that an effective dose suppressing tumor growth will be accompanied by relatively high toxicity. Moreover, caution should be taken when using Plk inhibitors as antitumor drugs, as all currently available compounds can also inhibit Plk3 activity at least in vitro. There is accumulating evidence that, in fact, Plk3 may act as a tumor suppressor, and that its undesired inhibition may thus induce secondary tumors (24) . Solving the crystal structure of the Plk1 kinase domain and identification of critical specificitydetermining residues will hopefully enable the development of a selective Plk1 inhibitor (25, 26) . An attractive alternative to inhibitors blocking the active site of Plk kinases is the development of compounds interfering with the binding abilities of the more diverse PBD domains, potentially yielding more selective inhibitors of Plk1 (27) . Many other compounds with activities directed against Plk and Aurora kinases are now beginning to emerge (28) (29) (30) (31) . Extensive research is clearly needed to validate specificities and relative efficiencies of all novel compounds. In this respect, in vitro kinase assays are widely used, usually followed by testing the phenotypes caused by an inhibitor treatment on tissue culture models. Establishment of the cell lines expressing biosensors, such as the Plk1 and Aurora-B FRET probes (5, 6) , may facilitate the validation of drug efficiency in vivo as well as screens for novel inhibitory compounds.
Conclusions and Future Directions
Development of novel tools such as small-molecule inhibitors and FRET-based biosensors have led to new insights into the role of Plk1 as a regulator of cell cycle progression. For instance, we have learned that Aurora-A and Plk1, two major mitotic kinases, regulate each other prior to and during mitosis, and that their activities are also needed for checkpoint recovery. However, at the molecular level, we still understand very little of how exactly this happens. How hBora helps Aurora-A to modify Plk1 is currently unclear. Because hBora does not seem to generally increase Aurora-A activity, hBora may possibly change the conformation of Plk1 and make the T-loop accessible for Aurora-A. Clearly, a crystal structure of the whole Plk1 (preferably in complex with hBora) is needed to resolve this issue. The location at which the initial activation of Plk1 occurs is also currently unknown. The activity measured by the Plk FRET probe first appears in the nucleus, whereas the activatory phosphorylation of the Thr-210 residue of Plk1 is seen on both the centrosomes and the kinetochores. Does the initial activation of Plk1 by Aurora-A occur on the centrosomes but remain undetected by the FRET probe until active Plk1 is translocated to the nucleus? Alternatively, the pThr-210 modification may not be sufficient to fully activate Plk1 in vivo until an additional activatory modification occurs in the nucleus. Recent phosphoproteomic screens revealed novel phosphorylation sites on Plk1 (7); however, their effect on Plk1 activity during the cell cycle awaits further validation. More data are also needed to determine which kinases are responsible for sustained pThr-210 phosphorylation of Plk1 during mitosis after degradation of hBora. At present, it is also unclear how the other members of the Plk family are regulated. Understanding the mechanism of Plk1 activation by Aurora-A in complex with its cofactor may open new avenues of research to resolve this issue. And, naturally determining the factors responsible for the initial activation of the Plk1 raises a new challenge of finding the activator for Aurora-A.
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